TrialBMC cancer2024

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.

Alexandra Leary et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.